| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
39,297 |
25,298 |
$3.64M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
3,613 |
2,468 |
$152.81 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
15,019 |
10,113 |
$99.68 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
9,900 |
6,608 |
$44.10 |
| 0072A |
|
122 |
28 |
$36.78 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
7,948 |
4,623 |
$27.39 |
| 92551 |
|
3,519 |
1,780 |
$15.82 |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,300 |
2,329 |
$2.77 |
| 81002 |
|
1,668 |
880 |
$2.54 |
| 99173 |
|
5,679 |
2,848 |
$1.91 |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
4,926 |
3,284 |
$0.00 |
| 90648 |
|
458 |
320 |
$0.00 |
| 90670 |
|
2,463 |
1,793 |
$0.00 |
| 86318 |
|
643 |
404 |
$0.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,214 |
1,371 |
$0.00 |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,717 |
3,072 |
$0.00 |
| 90649 |
|
481 |
216 |
$0.00 |
| 1160F |
|
3,327 |
2,397 |
$0.00 |
| 90633 |
|
1,527 |
978 |
$0.00 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
506 |
356 |
$0.00 |
| 99382 |
|
45 |
25 |
$0.00 |
| 90658 |
|
308 |
239 |
$0.00 |
| 90473 |
|
424 |
246 |
$0.00 |
| 81025 |
|
34 |
26 |
$0.00 |
| 90734 |
|
761 |
331 |
$0.00 |
| 90715 |
|
190 |
68 |
$0.00 |
| 83655 |
|
388 |
306 |
$0.00 |
| 96160 |
|
304 |
228 |
$0.00 |
| 90710 |
|
289 |
72 |
$0.00 |
| 90707 |
|
149 |
68 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
212 |
164 |
$0.00 |
| 0071A |
|
72 |
53 |
$0.00 |
| 90671 |
|
48 |
36 |
$0.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
16 |
14 |
$0.00 |
| 86703 |
|
384 |
223 |
$0.00 |
| 90700 |
|
27 |
26 |
$0.00 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
46 |
24 |
$0.00 |
| 90749 |
|
118 |
84 |
$0.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
14 |
13 |
$0.00 |
| 1039F |
|
93 |
65 |
$0.00 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
36 |
18 |
$0.00 |
| G8484 |
Influenza immunization was not administered, reason not given |
33 |
14 |
$0.00 |
| 1159F |
|
19 |
14 |
$0.00 |
| 90680 |
|
920 |
571 |
$0.00 |
| 90697 |
|
329 |
254 |
$0.00 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
409 |
301 |
$0.00 |
| 3008F |
|
4,101 |
2,963 |
$0.00 |
| 81099 |
|
818 |
583 |
$0.00 |
| 90656 |
|
291 |
211 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
279 |
178 |
$0.00 |
| 99381 |
|
157 |
111 |
$0.00 |
| 99343 |
|
41 |
36 |
$0.00 |
| 87430 |
|
387 |
256 |
$0.00 |
| 81001 |
|
1,418 |
975 |
$0.00 |
| 85018 |
|
2,419 |
1,288 |
$0.00 |
| 90651 |
|
434 |
307 |
$0.00 |
| 90696 |
|
288 |
83 |
$0.00 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
39 |
28 |
$0.00 |
| 90474 |
|
71 |
44 |
$0.00 |
| 87807 |
|
111 |
86 |
$0.00 |
| 90698 |
|
349 |
300 |
$0.00 |
| 90620 |
|
96 |
74 |
$0.00 |
| G0009 |
Administration of pneumococcal vaccine |
145 |
137 |
$0.00 |
| 2000F |
|
32 |
18 |
$0.00 |
| 91307 |
|
217 |
83 |
$0.00 |
| 90716 |
|
59 |
56 |
$0.00 |
| 90686 |
|
604 |
456 |
$0.00 |
| 90744 |
|
99 |
79 |
$0.00 |
| 90619 |
|
152 |
87 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
29 |
29 |
$0.00 |
| 90688 |
|
93 |
73 |
$0.00 |
| 90677 |
|
57 |
44 |
$0.00 |
| 4037F |
|
298 |
216 |
$0.00 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
19 |
12 |
$0.00 |
| 90732 |
|
19 |
13 |
$0.00 |
| 36416 |
|
165 |
135 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
79 |
43 |
$0.00 |
| 90723 |
|
96 |
82 |
$0.00 |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
18 |
14 |
$0.00 |
| 3351F |
|
12 |
12 |
$0.00 |
| 99383 |
|
20 |
19 |
$0.00 |
| 3079F |
|
21 |
16 |
$0.00 |